Related Experiment Video
Updated: Jun 3, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Pharmacogenomics in a community pharmacy: ACT now.
Lisa Padgett1, Shanna O'Connor, Mary Roederer
1Kerr Health Care Center, Kerr Drug, Chapel Hill, NC, USA. ladamspadgett@kerrdrug.com
Journal of the American Pharmacists Association : Japha
|March 9, 2011
Summary
Community pharmacists can leverage pharmacogenomic testing to optimize patient drug therapy. This involves using genetic information to tailor medication regimens, improving efficacy and reducing adverse effects.
Area of Science:
- Pharmacogenomics
- Genetics
- Drug Therapy Optimization
Background:
- Community pharmacists routinely optimize drug therapy using patient-specific information.
- Pharmacogenomics enables personalized medication management based on an individual's genetic makeup.
- Advances in pharmacogenomic technology facilitate testing in community pharmacy settings.
Purpose of the Study:
- To identify the opportunity for community pharmacists to offer pharmacogenomic testing and counseling.
- To emphasize the role of pharmacists in integrating pharmacogenomics into patient care.
Main Methods:
- Review of peer-reviewed pharmacy literature.
Main Results:
- Pharmacogenomic testing is now feasible in community pharmacies.
- Pharmacists are well-positioned to utilize genetic information for medication optimization.
- Patient access to community pharmacists presents a unique opportunity for pharmacogenomic services.
Conclusions:
- Pharmacists can lead in pharmacogenomics by providing testing, interpreting results, and educating patients and prescribers.
- Integrating pharmacogenomics requires pharmacists to possess specialized knowledge and skills.
- Pharmacists should assess clinical context to appropriately apply pharmacogenomics for enhanced drug therapy.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...